Abstract
The patterns of failure (POF) of metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab are not well described. If oligoprogression (OPD) occurs in a limited number of anatomic sites, local ablative therapy may allow continuation of otherwise effective immunotherapy (CPIs). We sought to characterize POF and OPD in this population and estimate the potential benefits of local therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
